Showing results (751-760 of 964) with videos related to

Sort By:
Pageof 97
Genome Research|September 6, 2005
A microarray analysis of the rice transcriptome and its comparison to ArabidopsisLigeng Ma, Chen Chen, Xigang Liu, et al.
The New England Journal of Medicine|August 16, 2013
Faldaprevir and deleobuvir for HCV genotype 1 infectionStefan Zeuzem, Vincent Soriano, Tarik Asselah, et al.
Transplantation Direct|April 20, 2023
The Hidden Epidemic: The Prevalence and Impact of Concurrent Liver Diseases in Patients Undergoing Liver Transplantation in Australia and New ZealandJess Howell, Avik Majumdar, Michael Fink, et al.
Journal of Viral Hepatitis|May 21, 2019
Efficacy and safety of a two-drug direct-acting antiviral agent regimen ruzasvir 180 mg and uprifosbuvir 450 mg for 12 weeks in adults with chronic hepatitis C virus genotype 1, 2, 3, 4, 5 or 6Eric Lawitz, Edward Gane, Jordan J Feld, et al.
American Journal of Medical Genetics. Part B, Neuropsychiatric Genetics : the Official Publication of the International Society of Psychiatric Genetics|September 27, 2005
Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutationDavid Hessl, Flora Tassone, Danuta Z Loesch, et al.
Journal of Hepatology|June 10, 2024
Efficacy, tolerability and pharmacokinetics of survodutide, a glucagon/glucagon-like peptide-1 receptor dual agonist, in cirrhosisEric J Lawitz, Mandy Fraessdorf, Guy W Neff, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|August 26, 2023
Chronic Hepatitis B Finite Treatment: Similar and Different Concerns With New Drug ClassesMarion G Peters, Man-Fung Yuen, Norah Terrault, et al.
Lancet (London, England)|October 19, 2010
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trialEdward J Gane, Stuart K Roberts, Catherine A M Stedman, et al.
Gastroenterology|June 15, 2016
Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and SofosbuvirChristoph Sarrazin, Hadas Dvory-Sobol, Evguenia S Svarovskaia, et al.
Plos One|December 10, 2015
ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV InfectionTarik Asselah, Stefan Zeuzem, Vicente Soriano, et al.
Pageof 97